Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Stopped Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.

Conditions

• Relapsed/Refractory Acute Myeloid Leukemia

Interventions

• DRUG: AMG 553

Sponsor

Amgen